FDA 505(b)(2) Policy Affirmed; Any Changes Will Be Too Late For Norvasc
Executive Summary
FDA will reconsider whether approval of new salt formulations under the Sec. 505(b)(2) process is appropriate, but any changes will not prevent approval of a pending competitor to Pfizer's antihypertensive Norvasc
You may also be interested in...
Dr. Reddy’s AmVaz Approval Stayed; FDA Reconsiders Norvasc Competitor
FDA's stay of Dr. Reddy's AmVaz suggests the agency is taking another look at the amlodipine maleate NDA to bolster its response to Pfizer's scientific argument against use of the 505(b)(2) approval pathway
Dr. Reddy’s AmVaz Approval Stayed; FDA Reconsiders Norvasc Competitor
FDA's stay of Dr. Reddy's AmVaz suggests the agency is taking another look at the amlodipine maleate NDA to bolster its response to Pfizer's scientific argument against use of the 505(b)(2) approval pathway
Apotex Challenges FDA “Shared” Generic Exclusivity Policy In Paxil Suit
TorPharm is challenging FDA's policy of awarding "shared" 180-day marketing exclusivity to multiple generic companies